How COVID-19 brought China vaccine play CanSino onto the global stage

CanSino has parlayed its COVID-19 program into a vehicle with which the Chinese vaccine company has entered the world stage, navigating global trial networks and regulators.

Convidecia, a single-shot adenovirus serotype 5 (Ad5) vector vaccine authorized in five countries, is the second authorized vaccine from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185), but the first the company markets outside China. Its other registered product is Ebola vaccine Ad5-EBOV...